AVIR
Price
$3.21
Change
+$0.08 (+2.56%)
Updated
Dec 20, 04:59 PM (EDT)
73 days until earnings call
NTLA
Price
$12.21
Change
+$0.13 (+1.08%)
Updated
Dec 20, 04:59 PM (EDT)
61 days until earnings call
Ad is loading...

AVIR vs NTLA

Header iconAVIR vs NTLA Comparison
Open Charts AVIR vs NTLABanner chart's image
Atea Pharmaceuticals
Price$3.21
Change+$0.08 (+2.56%)
Volume$31.83K
CapitalizationN/A
Intellia Therapeutics
Price$12.21
Change+$0.13 (+1.08%)
Volume$70.18K
CapitalizationN/A
AVIR vs NTLA Comparison Chart
Loading...
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVIR vs. NTLA commentary
Dec 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVIR is a Hold and NTLA is a Hold.

COMPARISON
Comparison
Dec 22, 2024
Stock price -- (AVIR: $3.21 vs. NTLA: $12.21)
Brand notoriety: AVIR and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVIR: 405% vs. NTLA: 129%
Market capitalization -- AVIR: $271.13M vs. NTLA: $1.24B
AVIR [@Biotechnology] is valued at $271.13M. NTLA’s [@Biotechnology] market capitalization is $1.24B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVIR’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • AVIR’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, AVIR is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVIR’s TA Score shows that 4 TA indicator(s) are bullish while NTLA’s TA Score has 4 bullish TA indicator(s).

  • AVIR’s TA Score: 4 bullish, 4 bearish.
  • NTLA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both AVIR and NTLA are a good buy in the short-term.

Price Growth

AVIR (@Biotechnology) experienced а +9.56% price change this week, while NTLA (@Biotechnology) price change was -5.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

AVIR is expected to report earnings on Mar 04, 2025.

NTLA is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.24B) has a higher market cap than AVIR($271M). AVIR YTD gains are higher at: 5.246 vs. NTLA (-59.954). AVIR has higher annual earnings (EBITDA): -200.08M vs. NTLA (-527.52M). NTLA has more cash in the bank: 658M vs. AVIR (483M). AVIR has less debt than NTLA: AVIR (1.84M) vs NTLA (102M). NTLA has higher revenues than AVIR: NTLA (43.1M) vs AVIR (0).
AVIRNTLAAVIR / NTLA
Capitalization271M1.24B22%
EBITDA-200.08M-527.52M38%
Gain YTD5.246-59.954-9%
P/E RatioN/AN/A-
Revenue043.1M-
Total Cash483M658M73%
Total Debt1.84M102M2%
FUNDAMENTALS RATINGS
AVIR vs NTLA: Fundamental Ratings
AVIR
NTLA
OUTLOOK RATING
1..100
1068
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
30
Undervalued
PROFIT vs RISK RATING
1..100
99100
SMR RATING
1..100
9597
PRICE GROWTH RATING
1..100
5992
P/E GROWTH RATING
1..100
95100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (30) in the Biotechnology industry is in the same range as AVIR (41). This means that NTLA’s stock grew similarly to AVIR’s over the last 12 months.

AVIR's Profit vs Risk Rating (99) in the Biotechnology industry is in the same range as NTLA (100). This means that AVIR’s stock grew similarly to NTLA’s over the last 12 months.

AVIR's SMR Rating (95) in the Biotechnology industry is in the same range as NTLA (97). This means that AVIR’s stock grew similarly to NTLA’s over the last 12 months.

AVIR's Price Growth Rating (59) in the Biotechnology industry is somewhat better than the same rating for NTLA (92). This means that AVIR’s stock grew somewhat faster than NTLA’s over the last 12 months.

AVIR's P/E Growth Rating (95) in the Biotechnology industry is in the same range as NTLA (100). This means that AVIR’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVIRNTLA
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 5 days ago
77%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 9 days ago
80%
Bearish Trend 4 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ACIWX12.820.21
+1.67%
American Century Global Real Estate G
LADPX21.070.29
+1.40%
Lord Abbett Developing Growth P
OIOIX16.660.08
+0.48%
AXS Income Opportunities I
MRSHX22.12N/A
N/A
MFS Research International R3
MUXRX25.27N/A
N/A
Victory S&P 500 Index R

AVIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVIR has been loosely correlated with VIR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AVIR jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVIR
1D Price
Change %
AVIR100%
+2.56%
VIR - AVIR
48%
Loosely correlated
-0.41%
HEPA - AVIR
47%
Loosely correlated
-7.22%
PGEN - AVIR
47%
Loosely correlated
+5.07%
AXON - AVIR
46%
Loosely correlated
+2.59%
INZY - AVIR
45%
Loosely correlated
+6.41%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+1.08%
VCYT - NTLA
69%
Closely correlated
+4.66%
EDIT - NTLA
68%
Closely correlated
-2.24%
BEAM - NTLA
66%
Loosely correlated
+8.16%
CRSP - NTLA
62%
Loosely correlated
+0.83%
PRME - NTLA
59%
Loosely correlated
+4.66%
More